Neurohumoral Effects of Aliskiren in Patients with Symptomatic Heart Failure Receiving a Mineralocorticoid Receptor Antagonist: The Aliskiren Observation of Heart Failure Treatment Study — Bertram Pitt (2011) | RDL Network
Neurohumoral Effects of Aliskiren in Patients with Symptomatic Heart Failure Receiving a Mineralocorticoid Receptor Antagonist: The Aliskiren Observation of Heart Failure Treatment Study
Aliskiren 150 mg added to standard HF therapy was well tolerated over 12 weeks and provided beneficial changes in neurohumoral biomarkers regardless of concomitant MRA treatment.
Muthiah Vaduganathan, Baljash Cheema, Erin R. Cleveland, K. Nathan Sankar, Haris Subačius, Gregg C. Fonarow, Scott D. Solomon, Eldrin F. Lewis, Stephen J. Greene, Aldo Maggioni, Michael Böhm, Faı̈ez Zannad, Javed Butler, Mihai Gheorghiade
Aldo Maggioni, Sally Greene, Gregg C. Fonarow, Michael Böhm, Faı̈ez Zannad, Scott D. Solomon, E. F. Lewis, Fabio Baschiera, Tien Hua, Claudio Gimpelewicz, Anastasia Lesogor, Mihai Gheorghiade, S. Ramos, Antoni Bayés de Luna, Santiago Miriuka, Maria Canto Diez, Enrico Perna, Hugo A Luquez, J. G. Pinna, Jorge Castagnino, Pedro Alvarenga, Joaquı́n Ibáñez,
Discussion(0)
No comments yet. Be the first to comment.